Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥48,354 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ¥479 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT Related Terms
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
SHSE:688796 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is ¥50,535 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ¥479 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a EV-to-EBIT of 105.50 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #358 out of 381 companies in the Biotechnology industry, placing it in the top 94%.
Is Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT too high?
Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBIT is 105.50. The Biotechnology industry median EV-to-EBIT is 14.08. Biocytogen Pharmaceuticals (Beijing) Co's value of 105.50 is 649.3% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #358 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #358 out of 381 companies for EV-to-EBIT. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median EV-to-EBIT is 14.08. Biocytogen Pharmaceuticals (Beijing) Co's value of 105.50 is 649.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBIT of 105.50 is 649.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBIT is 105.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥76.48, compared to a current price of ¥134.13 — trading 75.4% above its estimated fair value. The current EV-to-EBIT is 105.50 and 649.3% above the Biotechnology industry median of 14.08. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current EV-to-EBIT is 105.50 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥134.13 is trading 75.4% above its estimated GF Value™ of ¥76.48.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
EV-to-EBIT: 105.50
GF Value™: ¥76.48 vs. price of ¥134.13 (75.4% above fair value)
Industry Position: 649.3% above the Biotechnology median (#358 of 381)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
53GF Score
Get the complete analysis for SHSE:688796
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
